Results 81 to 90 of about 23,315 (198)
Antibiotic‐mediated immune modulation in periodontitis
Periodontology 2000, EarlyView.Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez +6 more
wiley +1 more source
Understanding exosomes in diabetic wound healing
Periodontology 2000, EarlyView.Abstract Background Diabetic wounds signify a major complication of diabetes mellitus, characterized by chronic inflammation, compromised angiogenesis, and high risk of infection, amputation, and mortality. Contemporary therapies remain limited in efficacy and durability.
Paras Ahmad +4 more
wiley +1 more source
Pioglitazone: Indian perspective
Indian Journal of Endocrinology and Metabolism, 2011 Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance.
Rishi Shukla, Sanjay Kalra
doaj
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed +8 more
wiley +1 more source
Metabolic Syndrome: From Mechanisms to Therapeutic Interventions
MedComm, Volume 7, Issue 9, September 2026.A comprehensive overview of molecular mechanisms delves into the potential disease mechanisms of metabolic syndrome, including complex mechanisms such as insulin resistance, chronic low‐grade inflammation, oxidative stress, and epigenetic modifications, and how these mechanisms contribute to the development of metabolic syndrome. Here, the relationship
Mengyao Yan, Qian Xiang
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2014 Masahiro Ohira,1 Takashi Yamaguchi,1 Atsuhito Saiki,1 Noriko Ban,1 Hidetoshi Kawana,1 Ayako Nagumo,1 Takeyoshi Murano,2 Kohji Shirai,3 Ichiro Tatsuno1 1Center for Diabetes, Endocrinology and Metabolism, 2Department of Clinical Laboratory Medicine ...
Ohira M +8 more
doaj
Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis
Andrology, Volume 14, Issue 6, Page 1627-1635, September 2026.ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin +3 more
wiley +1 more source
Risk management in the treatment of type 2 diabetes with pioglitazone
Diabetes, Metabolic Syndrome and Obesity, 2009 Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyIntroduction: Type 2 diabetes mellitus is one of the most important cardiovascular risk factors.
Giuseppe Derosa, Sibilla AT Salvadeo
doaj
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8378-8389, September 2026.ABSTRACT Aims The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis.
Ali A. Abdeen +5 more
wiley +1 more source